Fisetin, a naturally occurring senolytic compound, reversed vascular dysfunction and aortic stiffening induced by doxorubicin in mice by suppressing senescent cells and their inflammatory secretions, restoring nitric oxide availability. This demonstrates a pharmacological pathway to counter drug-induced premature vascular aging.
Key Points
- Fisetin suppressed senescent cells and reduced SASP inflammatory signaling
- Vascular endothelial function and aortic compliance improved significantly (p<0.001)
- Mitochondrial oxidative stress decreased, restoring nitric oxide bioavailability
Longevity Analysis
Doxorubicin cardiotoxicity remains a dose-limiting factor in cancer therapy, and this work identifies a tractable target for preserving vascular resilience in cancer survivors. By clearing senescent cells and their pro-inflammatory secretions, fisetin restores the capacity for vascular repair and hemodynamic function—core determinants of cardiovascular longevity. The mechanism operates through reducing cellular oxidative burden and restoring endothelial signaling capacity, suggesting senolytics may serve as a complementary strategy during and after chemotherapy to prevent premature vascular aging.
Original published by Wiley Aging Cell, by Mary A. Darrah, Sophia A. Mahoney, Ravinandan Venkatasubramanian, Nicholas S. VanDongen, Katelyn R. Ludwig, Douglas R. Seals, Matthew J. Rossman, Zachary S. Clayton .